SCHEMBL24162909

SCHEMBL24162909

COc1cccc(-c2nc3ccc(C(=O)N(C)Cc4nnc(C)o4)cc3o2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.50
▸ RAB9A P51151 8/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ HSP90AA1 P07900 1/20 0.50
▸ POLB P06746 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ HSD17B2 P37059 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24163917 0.83 NPC1 (0.51) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24163750 0.82 NPC1 (0.48) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24163482 0.79 NPC1 (0.56) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24162918 0.79 NPC1 (0.51) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24163740 0.79 RAB9A (0.49) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24162900 0.79 NPC1 (0.51) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL1675462 0.77 NPC1 (0.63) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24162901 0.75 NPC1 (0.56) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL24163871 0.71 NPC1 (0.59) NPC1RAB9AKMT2AHSP90AA1POLB
SCHEMBL4052772 0.71 NPC1 (0.69) NPC1RAB9AKMT2AHSP90AA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255906-A1 Targeting Serpin B9 in Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-08-17 — — US claimed
US-20230255906-A1 Targeting Serpin B9 in Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-08-17 — — US disclosed
US-20230255906-A1 Targeting Serpin B9 in Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-08-17 — — US disclosed
US-20230255906-A1 Targeting Serpin B9 in Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-08-17 — — US disclosed
WO-2022006534-A1 TARGETING SERPIN B9 IN CANCER THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2022-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255906-A1 Targeting Serpin B9 in Cancer SERPINB10, SERPINB8, SERPINE1 NPC1 1048/4885RAB9A 338/4885KMT2A 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback